Oncotelic Therapeutics Reports FY 2025 Net Income of $249M Driven by JV Fair Value Gain

Oncotelic Therapeutics, Inc.

2026-Q1 EPS reported $0.00

Net income attributable to Oncotelic was $249.3M in FY 2025, compared to net loss of $4.5M in FY 2024.
Non-cash gain of $365.4M from fair value increase in GMP Bio JV investment, partially offset by $111.6M deferred tax provision.
JV subsidiaries Sapu Bio and Sapu Nano formalized; OT-101 Phase 1 combo trial completed and Phase 2/3 pancreatic cancer enrolling.
Deciparticle nanoparticle platform advancing six candidates; everolimus trial enrolling in Australia, INDs expected for palbociclib and docetaxel in 2026.
PDAOAI AI platform expanded to over 100,000 curated abstracts, contributing to seven peer-reviewed publications in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.